HSP90AA1 and neoplasm: Accordingly, combining Hsp90 inhibitors with checkpoint blockade antibodies, particularly anti-PD-1, has demonstrated enhanced antitumor efficacy in preclinical models by alleviating tumor-mediated immune suppression and enhancing T cell cytotoxicity [143,144].